Intellia Therapeutics stock has had a difficult longer term run, with the share price down about 92.1% over the past five years. However, recent gains and current market multiples now point to a company that screens as expensive rather than a clear bargain.
- The roughly 92.1% share price decline over five years highlights how much long term investors have already seen expectations reset.
- Future valuation for Intellia Therapeutics can hinge on how effectively its gene editing programs translate into commercial revenue, while ongoing development costs and funding needs remain a key risk.
- On a broad set of valuation checks, Intellia Therapeutics scores 2 out of 6, which leans expensive rather than offering clear value.
The issue now is whether the current price for Intellia Therapeutics stock already reflects the realistic payoff from its pipeline, or if there is still room for long term upside relative to the risks.
Balance the sharp reset in Intellia Therapeutics with other options by scanning hand picked 52 high quality undervalued stocks that currently screen as cheaper on fundamentals.
Is Intellia Therapeutics Getting Expensive on Sales?
P/S is often the cleaner yardstick for Intellia Therapeutics because the company is still reporting losses and does not yet have positive earnings to support a P/E comparison. Revenue is the anchor here rather than profits.
On this basis, Intellia Therapeutics trades on a P/S of about 29.9x. That is more than double the broader biotech industry average of 13.1x and also above the peer group average of 24.0x. The tailored fair ratio from the model is 0.1x, which is far below the current market multiple. The model is heavily penalising the company’s current losses, risk profile and revenue base. As a result, this fair ratio is best viewed as a warning signal that the stock price reflects a high level of optimism on sales rather than a precise target.
Overall, Intellia Therapeutics appears overvalued on its current P/S multiple relative to industry norms and the model’s fair ratio signal.
See what the numbers say about this price — find out in our valuation breakdown.
The Intellia Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Intellia Therapeutics give you a structured way to link the high P/S multiple to concrete expectations for Intellia Therapeutics' future growth, margins and eventual earnings path. Each narrative ties a fair value estimate to a specific story about the company’s potential catalysts and key risks, so you can track over time which version of events appears to be unfolding on Simply Wall St's Community page.
One of the top community narratives on Intellia Therapeutics: 47% undervalued
"Growing patient and physician enthusiasm for Intellia's lead in vivo CRISPR therapies is driving faster than expected enrollment across multiple late-stage clinical trials…"
Read one of the top narratives on Intellia Therapeutics
Do you think there's more to the story for Intellia Therapeutics? Head over to our Community to see what others are saying!
The Bottom Line
Intellia Therapeutics now screens as overvalued on simple market multiples, with a wide gap between its current P/S ratio and the model’s fair ratio signal. That gap reflects a lot of optimism already embedded in the share price while the company is still loss making and funding its pipeline. For you, the key question is whether Intellia Therapeutics can convert its gene editing programs into a revenue base that eventually justifies that optimism, or whether the valuation leaves too little room for disappointment.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com